Vimarsana
Biggest News Aggregation in the World

Clinical Endpoints News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Clinical Endpoints. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Clinical Endpoints Today - Breaking & Trending Today

Aeglea BioTherapeutics : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Form 8-K -November 15, 2023 at 05:18 pm EST - Vimarsana News

Aeglea BioTherapeutics : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Form 8-K -November 15, 2023 at 05:18 pm EST

Published: November 15, 2023

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following discussion and analysis of our financial...

Source: marketscreener.com
Related Topics:
San MarinoUnited StatesUnited KingdomUnited Arab EmiratesSaudi ArabiaVatican CityResearch Institute Of TexasAemase IncCompany Or AegleaEuropean UnionEuropean Medicines AgencyAeglea Biotherapeutics IncDevelopment ExpensesJonestrading Institutional ServicesUniversity Of Texas At AustinAecase IncDrug AdministrationCancer Research Grant ContractDevelopment Fee RevenueAnnual ReportClassical HomocystinuriaPegzilarginase EffectClinical EndpointsMarketing Authorization ApplicationImmedica Pharma
Acumen Pharmaceuticals : CTAD Symposium Presentation 2023 -October 27, 2023 at 10:37 am EDT - Vimarsana News

Acumen Pharmaceuticals : CTAD Symposium Presentation 2023 -October 27, 2023 at 10:37 am EDT

Published: October 27, 2023

INTERCEPT-AD phase 1 insights and findings from the investigation of ACU193, a monoclonal antibody...

Source: marketscreener.com
Related Topics:
United StatesSanjiv Sharma CenexelEric SiemersDavid Weisman AbingtonStephen SallowayDiana KerwinMaria JohnsonMichaelis Menten EmaxKimball JohnsonGustavo Alva HoagShirley Valdez Arroyo Santos Research CenterMohammad Reza Bolouri Alzheimer Memory CenterEric Carbonell Combined ResearchResearch AtlantaAcumen PharmaceuticalsAlida Reinoso Columbus Clinical ServicesJeffrey Norton Charter ResearchDiana Kerwin Research CenterExchange CommissionNelson Berrios Clinical Trial NetworkAlexander White Progressive Medical ResearchAcumen Pharmaceuticals IncAlpert Medical School Of Brown UniversityKerwin Medical CenterStudy Team Members
Teva to Present Data for AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, AUSTEDO® (deutetrabenazine) Tablets and UZEDY™ (risperidone) Extended-Release Injectable Suspension at Psych Congress 2023 - Vimarsana News

Teva to Present Data for AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, AUSTEDO® (deutetrabenazine) Tablets and UZEDY™ (risperidone) Extended-Release Injectable Suspension at Psych Congress 2023

Published: September 6, 2023

Teva will share 16 data presentations across its neuroscience portfolio including AUSTEDO, once-daily AUSTEDO XR, UZEDY, TV-44749 and AJOVY® injection Presentation highlights include data for...

Source: marketscreener.com
Related Topics:
United StatesEric HughesTeva PharmaceuticalsMental Health Services AdministrationPsych Congress OnTeva Neuroscience IncNational Alliance On Mental IllnessDrug AdministrationTeva Pharmaceutical Industries LtdNational Pregnancy Registry For Atypical AntipsychoticsTeva Pharmaceutical IndustriesPsych CongressExecutive Vice PresidentChief Medical OfficerClinician FactorsDefeating BarriersTardive DyskinesiaTreatment PatternsDeutetrabenazine When Initiated UsingWeek Patient Titration KitInterim ResultsReal World EffectivenessPopulation EstimatePatients With Tardive DyskinesiaReal World Clinical Practice
Teva to Present Data for AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, AUSTEDO® (deutetra - Vimarsana News

Teva to Present Data for AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, AUSTEDO® (deutetra

Published: September 6, 2023

Teva will share 16 data presentations across its neuroscience portfolio including AUSTEDO, once-daily AUSTEDO XR, UZEDY, TV-44749 (olanzapine) and AJOVY® (fremanezumab) injectionPresentation highlights include data for AUSTEDO in the tardive dyskinesia (TD) START study on real-world effectiveness and adherence when...

Source: pharmiweb.com
Related Topics:
Eric HughesYael AshmanSanjeev SharmaTeva Pharmaceutical Industries LtdDrug AdministrationTeva PharmaceuticalsPsych Congress OnWeek Patient Titration KitRisperidone Subcutaneous Extended Release StudyMaintenance TreatmentDetermining Clinician FactorsDefeating BarriersTeva Pharmaceutical IndustriesPsych CongressExecutive Vice PresidentChief Medical OfficerClinician FactorsTardive DyskinesiaTreatment PatternsDeutetrabenazine When Initiated UsingInterim ResultsReal World EffectivenessPopulation EstimatePatients With Tardive DyskinesiaReal World Clinical Practice
Landmark NAD3® human study shows improvements in cellular NAD+ status and biomarkers of cardiovascular health - Vimarsana News

Landmark NAD3® human study shows improvements in cellular NAD+ status and biomarkers of cardiovascular health

Published: May 5, 2022

Carlsbad, CA (PRWEB) May 05, 2022 -- NAD3® is a multi-patents-pending nutraceutical containing a unique Wasabi Japonica extract, Theacrine and

Source: prweb.com
Related Topics:
Solutions IncClinical Endpoints Of HealthWasabi JaponicaTotal CholesterolCompound SolutionsClinical EndpointsMiddle Aged AdultsPress Release